In this podcast, Dr. Sumanta (Monty) Pal discusses a recent study examining the effect of aspirin use on prostate cancer. The researchers who led this study found that men who took aspirin regularly after a diagnosis of prostate cancer were less likely to die from the disease.
“This study suggests there may be yet one more benefit of aspirin, beyond those we’ve already seen in colorectal cancer and heart disease,” said Dr. Pal, ASCO Spokesperson. “While taking aspirin does carry certain side effects that patients should discuss with their physician, it’s intriguing that this low-cost medicine may lower the risk of death from prostate cancer.”
Listen in to learn more about this study and what it means for patients.
This is a prerecorded audio podcast, and it can be listened to online or downloaded to your computer. A transcript of this podcast is also available. For more information, visit the Cancer.Net podcast page.
Other research highlights
Two other studies were highlighted in advance of this year’s symposium, held January 7th through the 9th. These include new research on prostate cancer and kidney cancer:
An early study found that an experimental blood test may be able to predict how well hormone therapy for prostate cancer will work for each patient.
Researchers studying kidney cancer found that the drug cabozantinib (Cometriq) may become a new option for people with advanced kidney cancer who have already received treatment.
Find out more at about all of the research highlighted at the 2016 Genitourinary Cancers Symposium.